Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
JAGX · NASDAQ · Pharmaceutical Preparations
Jaguar Health (JAGX) · oqro.io/stocks/JAGX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Jaguar Health was filed in the last 90 days. The latest on record was on Dec 31, 2022.
Since 2016, Jaguar Health insiders reported 13 open-market purchases and 3 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2022.
No open-market sale by an insider of Jaguar Health (JAGX) was filed with the SEC in the last 90 days.
No trade in Jaguar Health (JAGX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.227−0.10 (−30.58%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−100.0% (−$650.77) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $651.00 on Nov 20, 2025 to $0.227 on Nov 20, 2026 (−100.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Francisco, Ca.
Last 12 months
−100.0%
Market value
$1.17M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 201K shares sold short (3.9% of shares outstanding), +42.8% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$11.5M
−1.5% vs the year before
Net income, fiscal 2025
−$53.6M
A loss for the year
Shares outstanding
5.17M
As of Aug 14, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No Schedule 13D or 13G filing on JAGX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Revenue
$2.34M
−24.0% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $5.53M, at Sep 30, 2026
Net income, last 12 months
—
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 16, 2026.
Revenue and earnings history, 12 fiscal yearsEarnings dates and the stock's moves
Insiders of Jaguar Health reported 13 open-market purchases and 3 sales since 2016; purchases in 6 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $101×1 trade | — |
| 2021 | $40K2×2 trades | $7752×2 trades |
| 2019 | $387K2×2 trades | — |
| 2018 | $35K6×6 trades | $596K1×1 trade |
| 2017 | $50K1×1 trade | — |
| 2016 | $400K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
Nov 16, 2026
Within the 30 days after it, until Dec 16, 2026
Next results, expected
Not announced
Purchases after results
45%
5 of 11 insider purchases since 2017 came within 30 days after a results announcement
From Jaguar Health's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Jaguar Health's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Deals
Things to keep in mind
Off-exchange trading: 53.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.5% on ATS, 47.7% with other brokers), close to its 4-week average of 53.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (19.7%), BOATS (12.5%), IBKR ATS (9.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Apr 7, 2026. Read the filing
−1.9% on the year before ($11.4M)
+12% on the year before ($315K)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
Jaguar Health, Inc. (“Jaguar”), in conjunction with Jaguar family company Napo Pharmaceuticals, Inc. (“Napo”), develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states. Jaguar family companies Napo and Napo Therapeutics, S.p.A., an Italian corporation Jaguar established in Milan, Italy in 2021, are focused on expanding global crofelemer access and are developing new therapies for orphan and rare GI conditions. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications.
And 17 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Apr 7, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Apr 7, 2026, compared with the one filed Mar 31, 2025. Read the filing
From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, litigation can have a material adverse effect on us due to defense and settlement costs, diversion of our management resources, and other factors. We are not currently subject to any material legal proceedings.
Source: SEC EDGAR, Form 10-K filed Apr 7, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Said its annual or quarterly report would be late
“Jaguar Health, Inc. (the “Registrant”) could not complete the filing of its Annual Report on Form 10-Q for the quarter ended June 30, 2026 (the “Form 10-Q”) due to a delay in obtaining and compiling information required to be included in the Form 10-Q including significant and material subsequent event transactions, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In acco”
NT 10-Q on sec.govSaid its annual or quarterly report would be late
“Jaguar Health, Inc. (the “Registrant”) could not complete the filing of its Annual Report on Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) due to a delay in obtaining and compiling information required to be included in the Form 10-Q including significant and material subsequent event transactions, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In acc”
NT 10-Q on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
“The Registrant could not complete the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) due to a delay in obtaining and compiling information required to be included in the Form 10-K including significant and material subsequent event transactions, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule”
NT 10-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.